<DOC>
	<DOCNO>NCT01953887</DOCNO>
	<brief_summary>A study assess amount drug blood young middle age , healthy , male subject receive final formulation EC905 compare solifenacin ( Vesicare® ) tamsulosin OCAS ( Omnic OCAS® ) . Subjects give single dose combination tablet EC905 , Vesicare® Omnic OCAS® 3 separate period .</brief_summary>
	<brief_title>A Study Compare Amount Drug Blood After Single Tablet EC905 Containing Solifenacin Tamsulosin Taken Healthy Males Compared Separate Tablets Solifenacin Tamsulosin</brief_title>
	<detailed_description>The subject randomize one 6 treatment sequence group . Subjects admit clinical unit Day -1 pre-dose assessment . They remain clinic two period 11 day one period 14 day . After randomization subject receive single dose treatment Day 1 follow blood sample pharmacokinetic ( PK ) assessment . For EC905 Vesicare® , blood sampling continue 10 day dose ; Omnic OCAS® , continue 3 day dose . Each period separate wash-out period least 4 day , subject check eligibility one day prior start new dose day . Vital sign , safety ECG measurement , safety laboratory assessment , adverse event concomitant medication monitor throughout investigational period . A blood sample drawn CYP2D6 genotyping , order evaluate effect CYP2D6 genotype PK tamsulosin . Subjects return End Study Visit ( ESV ) 7 day last on-site period , withdrawal .</detailed_description>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Body Mass Index 18.5 30.0 kg/m2 , inclusive Known suspect hypersensitivity solifenacin , tamsulosin , EC905 , Vesicare , Omnic OCAS component formulation use . Any contraindication precaution use mention applicable section SPC 's tamsulosin solifenacin . Use grapefruit ( 3 x 200 ml ) marmalade ( three time ) week prior admission Clinical Unit , report subject . Positive serology test HBsAg , anti HAV ( IgM ) , antiHCV antiHIV 1+2</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Final formulation EC905</keyword>
	<keyword>Solifenacin succinate</keyword>
	<keyword>Tamsulosin HCl</keyword>
	<keyword>Marketed drug</keyword>
</DOC>